251 related articles for article (PubMed ID: 31231567)
1. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.
Aoki M; Shoji H; Nagashima K; Imazeki H; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Higuchi K; Boku N
ESMO Open; 2019; 4(3):e000488. PubMed ID: 31231567
[TBL] [Abstract][Full Text] [Related]
2. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
Aoki M; Kadowaki S; Takahashi N; Suzuki T; Oshima K; Ando T; Yamamoto Y; Kawakami K; Kito Y; Matsumoto T; Shimozaki K; Miyazaki Y; Yamaguchi T; Nagase M; Tamura T; Amanuma Y; Esaki T; Miura Y; Akiyoshi K; Baba E; Makiyama A; Negoro Y; Nakashima K; Sugimoto N; Nagashima K; Shoji H; Boku N
Gastric Cancer; 2023 Jan; 26(1):132-144. PubMed ID: 36316527
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
Kim CG; Hong M; Jeung HC; Lee G; Chung HC; Rha SY; Kim HS; Lee CK; Lee JH; Han Y; Kim JH; Lee SY; Kim H; Shin SJ; Baek SE; Jung M
Eur J Cancer; 2022 Sep; 172():387-399. PubMed ID: 35839733
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08).
Takahashi Y; Sunakawa Y; Inoue E; Kawabata R; Ishiguro A; Kito Y; Akamaru Y; Takahashi M; Yabusaki H; Matsuyama J; Makiyama A; Tsuda M; Suzuki T; Yasui H; Matoba R; Kawakami H; Nakajima TE; Muro K; Ichikawa W; Fujii M
Gastric Cancer; 2022 Jan; 25(1):235-244. PubMed ID: 34427838
[TBL] [Abstract][Full Text] [Related]
7. Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer.
Kubota Y; Yoshimura K; Hamada K; Hirasawa Y; Shida M; Taniguchi M; Matsui H; Ariizumi H; Ishiguro T; Suzuki N; Ohkuma R; Sambe T; Ishida H; Horiike A; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Kobayashi S; Tsunoda T
In Vivo; 2021; 35(3):1865-1875. PubMed ID: 33910874
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer.
Ishii T; Kawazoe A; Sasaki A; Mishima S; Kentaro S; Nakamura Y; Kotani D; Kuboki Y; Taniguchi H; Kojima T; Doi T; Yoshino T; Kuwata T; Ishii G; Shitara K
Ther Adv Med Oncol; 2020; 12():1758835920942377. PubMed ID: 32733607
[TBL] [Abstract][Full Text] [Related]
9. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
Kim SH; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
[TBL] [Abstract][Full Text] [Related]
11. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Yumita S; Ogasawara S; Nakagawa M; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kogure T; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Kato J; Kato N
BMC Gastroenterol; 2023 Mar; 23(1):101. PubMed ID: 37003980
[TBL] [Abstract][Full Text] [Related]
12. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
[TBL] [Abstract][Full Text] [Related]
13. Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study.
Petrioli R; Mazzei MA; Giorgi S; Cesqui E; Gentili F; Francini G; Volterrani L; Francini E
Anticancer Drugs; 2020 Feb; 31(2):190-195. PubMed ID: 31850916
[TBL] [Abstract][Full Text] [Related]
14. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.
Rocha P; Ramal D; Ripoll E; Moliner L; Corbera A; Hardy-Werbin M; Orrillo M; Taus Á; Zuccarino F; Gibert J; Perera-Bel J; Casadevall D; Arriola E
JTO Clin Res Rep; 2021 Jan; 2(1):100115. PubMed ID: 34589976
[TBL] [Abstract][Full Text] [Related]
16. Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer.
Kato K; Masuishi T; Fushiki K; Nakano S; Kawamoto Y; Narita Y; Tsushima T; Harada K; Kadowaki S; Todaka A; Yuki S; Tajika M; Machida N; Komatsu Y; Yasui H; Muro K; Kawakami T
ESMO Open; 2021 Aug; 6(4):100179. PubMed ID: 34119801
[TBL] [Abstract][Full Text] [Related]
17. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study.
Narita Y; Matsushima T; Sakamoto Y; Matsuoka H; Tanioka H; Kawakami T; Shoji H; Mizukami T; Izawa N; Nishina T; Yamamoto Y; Mitani S; Nakamura M; Misumi T; Muro K
ESMO Open; 2023 Dec; 8(6):102071. PubMed ID: 38016249
[TBL] [Abstract][Full Text] [Related]
19. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer.
Hagi T; Kurokawa Y; Kawabata R; Omori T; Matsuyama J; Fujitani K; Hirao M; Akamaru Y; Takahashi T; Yamasaki M; Satoh T; Eguchi H; Doki Y
Br J Cancer; 2020 Sep; 123(6):965-972. PubMed ID: 32616848
[TBL] [Abstract][Full Text] [Related]
20. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
